[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Haibo Shao\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":68},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,46],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100635840","phase-2-epalrestat-combined-with-haic-donafenib-and-tislelizumab-as-first-line-treatment-for-patients-with-unresectable-hcc-and-diabetes-100635840",false,"NCT07557914","Epalrestat Combined With HAIC, Donafenib and Tislelizumab as First-line Treatment for Patients With Unresectable HCC and Diabetes","A Multicenter, Prospective, Single-arm Clinical Study Evaluating the Efficacy and Safety of Epalrestat Combined With Hepatic Arterial Chemotherapy Infusion (HAIC), Donafenib and Tislelizumab as First-line Treatment for Patients With Unresectable Hepatocellular Carcinoma and Diabetes","Inclusion Criteria:\n\n1. Diabetes mellitus combined with unresectable advanced HCC (BCLC stage C);\n2. Patients who have the need for treatment, prevention and improvement of diabetic neuropathy;\n3. Liver function at Child-Pugh grade A or B (≤ 7 points), ECOG PS 0-1;\n4. Age 18-80 years old. Confirmed as unrectable HCC through pathological or imaging diagnosis;\n\nExclusion Criteria:\n\n1. Severe liver dysfunction: Child-Pugh C grade (≥ 8 points) or active hepatic encephalopathy Illness;\n2. Extensive extrahepatic metastases (e.g., lung, bone, or peritoneum metastases);\n3. Severe cardiovascular diseases: Uncontrolled heart failure, recent myocardial infarction;\n4. Renal failure: Creatinine clearance rate \\\u003C 30 mL\u002Fmin;\n5. Thrombocytopenia (less than 50×10⁹\u002FL) or coagulation dysfunction (INR greater than 1.5);\n6. Active infection (such as uncontrolled hepatitis B virus replication with HBV-DNA \\> 2000 IU\u002FmL);\n7. ECOG PS ≥ 2 or extremely poor overall condition;\n8. Diabetic patients with acute ketoacidosis or during the period of severe infection;\n9. Pregnant and lactating women;\n10. Known history of other malignancy.","ALL","18 Years","80 Years",{"count":20,"type":21},32,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","The purpose of this study is to evaluate the comprehensive therapeutic efficacy and safety profile of the epalrestat combined with hepatic artery infusion chemotherapy (HAIC), donafenib and tislelizumab quadruple regimen in patients with unresectable hepatocellular carcinoma (HCC) and diabetes.",[27,28],"HCC - Hepatocellular Carcinoma","Diabetes",[30,31,32,27,28],"hepatic arterial infusion chemotherapy","Donafenib","Tislelizumab","NOT_YET_RECRUITING","2026-06-01",{"date":36,"type":37},"2026-06-03","ACTUAL",{"date":39,"type":21},"2026-06",{"date":41,"type":21},"2029-02",{"name":43,"class":44},"Haibo Shao","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":55,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":4},"100638413","clinical-study-on-the-effects-of-pulmonary-vessels-on-cryoablation-and-preventive-embolization-strategies-100638413","NCT07594834","Clinical Study on the Effects of Pulmonary Vessels on Cryoablation and Preventive Embolization Strategies","This Study Aims to Provide New Evidence for Optimizing the Lung Cryoablation Strategy by Targeting High-risk Individuals With Incomplete Ice Ball Morphology in Lung Cryoablation. This is Achieved Through the Use of Selective Pulmonary Artery Embolization.","Inclusion Criteria:\n\n1. Individuals at high risk of incomplete ablation (for example, there are vessels with a diameter greater than 3mm within 1cm around the pulmonary nodule);\n2. Scheduled for lung cryoablation, meeting the surgical indications and without any specific contraindications;\n3. The long diameter of the lung tumor is less than 3cm;\n4. The single cryoablation needle will be used. -\n\nExclusion Criteria:\n\n1. Postoperative complications such as massive pneumothorax and bleeding occurred, which affected the observation of the ice ball's shape;\n2. Poor image quality or incomplete images. -",{"count":54,"type":21},20,[56],"NA","This study targeted high-risk individuals with incomplete ablation and performed selective pulmonary artery embolization before lung cryoablation, which could enhance the therapeutic effect and reduce the risk of intraoperative bleeding. Previous studies have shown that selective pulmonary artery embolization before ablation has no adverse reactions related to embolization. In this study, gelatin sponge particles were used for selective pulmonary artery embolization. Gelatin sponge is an absorbable embolic material that can be absorbed and degraded in the human body within about 7 days, which has high safety and a low probability of adverse reactions. The surgical risks are detailed in the surgical protocol. The study aims to optimize the lung cryoablation strategy for high-risk individuals with incomplete ablation, aiming to improve the prognosis of high-risk recurrent patients. The two groups of patients underwent lung CT reexamination every three months after surgery to observe the tumor ablation situation.",[59],"Lung Cancer","2026-05-17",{"date":62,"type":37},"2026-05-19",{"date":64,"type":21},"2026-06-30",{"date":66,"type":21},"2030-06-30",{"name":43,"class":44},""]